Muhaj Fiorinda, Karri Padmavathi V, Moody Wylie, Brown Alexandria, Patel Anisha B
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Dermatology, University of Texas Health Science Center- Houston, Houston, TX, United States.
Front Allergy. 2023 Mar 2;4:1147513. doi: 10.3389/falgy.2023.1147513. eCollection 2023.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Since the approval of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and hematologic malignancies. The expanding use of ICIs in oncology underscores the need for diagnosis and treatment expertise in immune related adverse events (irAE). Cutaneous toxicities are the earliest and most common irAE in this class of therapy. In addition to the more frequent reactions including vitiligo, lichenoid dermatitis, psoriasiform dermatitis, other less common skin toxicities including bullous dermatoses, neutrophilic dermatoses, and autoimmune dermato-rheumatologic diseases have been reported. Even though less than 3% of cutaneous irAEs (irCAEs) are classified as grade 3 or higher events, irCAEs can greatly impact quality of life. Appropriate management of irCAEs is critical to avoid unwarranted interruptions or discontinuation of lifesaving immunotherapy.
免疫检查点抑制剂(ICIs)彻底改变了癌症治疗方式。自2011年伊匹单抗获批以来,共有九种ICIs已获批用于各种实体瘤和血液系统恶性肿瘤。ICIs在肿瘤学领域的广泛应用凸显了对免疫相关不良事件(irAE)诊断和治疗专业知识的需求。皮肤毒性是这类治疗中最早出现且最常见的irAE。除了更常见的反应,如白癜风、苔藓样皮炎、银屑病样皮炎外,还报告了其他不太常见的皮肤毒性,包括大疱性皮肤病、嗜中性皮肤病和自身免疫性皮肤 - 风湿性疾病。尽管不到3%的皮肤irAE(irCAEs)被归类为3级或更高级别事件,但irCAEs会对生活质量产生重大影响。对irCAEs进行适当管理对于避免不必要地中断或停止挽救生命的免疫治疗至关重要。